ArticleMolecular therapy : the journal of the American Society of Gene Therapy2023
Augmenting TCR signal strength and ICOS costimulation results in metabolically fit and therapeutically potent human CAR Th17 cells.
Open access · greenAbstract read
In one paragraph
Article in Molecular therapy : the journal of the American Society of Gene Therapy, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
3.0field-weighted citation impact, top 8% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 13 citations in OpenAlex.
- A Multi-Targeting Chimeric Antigen Receptor-T Cell Platform to Overcome Antigen Heterogeneity in the Treatment of Non-Small Cell Lung Cancer.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- T cell receptors equipped with ICOS provide T cells with durable anti-tumor response.Molecular cancer · 2026Article
- Contextualizing TNature reviews. Immunology · 2026Review
- Metabolic reprogramming of CAR-T cells: a multi-pronged strategy to conquer the immunosuppressive tumor microenvironment.Cell communication and signaling : CCS · 2026Review
- Integrating T cell signaling and metabolism to enhance T cell engager responses in solid tumors.Frontiers in immunology · 2026Review
- CAR-T and CAR-NK as cellular cancer immunotherapy for solid tumors.Cellular & molecular immunology · 2024Review
- Review
- Human IL-17A protein production is controlled through a PIP5K1α-dependent translational checkpoint.Science signaling · 2023Article
- Factors impacting the benefits and pathogenicity of Th17 cells in the tumor microenvironment.Frontiers in immunology · 2023Review
- The Impact of the Intracellular Domains of Chimeric Antigenic Receptors on the Properties of CAR T-cells.Acta naturaeArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 3 institutions in 1 country.
Megan M WyattDepartment of Surgery: Oncology, Winship Cancer Institute of Emory University, Atlanta, GA 30322, USA; Department of Microbiology and Immunology, Emory University, Atlanta, GA 30322, USA; Department of Microbiology and Immunology, Hollings Cancer Institute, Medical University of South Carolina, Charleston, SC 29425, USA. Electronic address: megan.meek.wyatt@emory.edu.
Logan W HuffDepartment of Microbiology and Immunology, Hollings Cancer Institute, Medical University of South Carolina, Charleston, SC 29425, USA.
Michelle H NelsonDepartment of Microbiology and Immunology, Hollings Cancer Institute, Medical University of South Carolina, Charleston, SC 29425, USA.
Lillian R NealDepartment of Microbiology and Immunology, Hollings Cancer Institute, Medical University of South Carolina, Charleston, SC 29425, USA.
Andrew R MedvecDepartment of Microbiology, Center for Cellular Immunotherapies, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA.
Guillermo O Rangel RiveraDepartment of Surgery: Oncology, Winship Cancer Institute of Emory University, Atlanta, GA 30322, USA; Department of Microbiology and Immunology, Emory University, Atlanta, GA 30322, USA; Department of Microbiology and Immunology, Hollings Cancer Institute, Medical University of South Carolina, Charleston, SC 29425, USA.
Aubrey S SmithDepartment of Surgery: Oncology, Winship Cancer Institute of Emory University, Atlanta, GA 30322, USA; Department of Microbiology and Immunology, Emory University, Atlanta, GA 30322, USA; Department of Microbiology and Immunology, Hollings Cancer Institute, Medical University of South Carolina, Charleston, SC 29425, USA.
Amalia M Rivera ReyesDepartment of Surgery: Oncology, Winship Cancer Institute of Emory University, Atlanta, GA 30322, USA; Department of Microbiology and Immunology, Emory University, Atlanta, GA 30322, USA; Department of Microbiology and Immunology, Hollings Cancer Institute, Medical University of South Carolina, Charleston, SC 29425, USA.
Hannah M KnochelmannDepartment of Surgery: Oncology, Winship Cancer Institute of Emory University, Atlanta, GA 30322, USA; Department of Microbiology and Immunology, Emory University, Atlanta, GA 30322, USA; Department of Microbiology and Immunology, Hollings Cancer Institute, Medical University of South Carolina, Charleston, SC 29425, USA.
James L RileyDepartment of Microbiology, Center for Cellular Immunotherapies, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA.
Gregory B LesinskiDepartment of Hematology and Medical Oncology, Winship Cancer Institute of Emory University, Atlanta, GA 30322, USA.
Chrystal M PaulosDepartment of Surgery: Oncology, Winship Cancer Institute of Emory University, Atlanta, GA 30322, USA; Department of Microbiology and Immunology, Emory University, Atlanta, GA 30322, USA; Department of Microbiology and Immunology, Hollings Cancer Institute, Medical University of South Carolina, Charleston, SC 29425, USA. Electronic address: cpaulos@emory.edu.
Emory University · USMedical University of South Carolina · USUniversity of Pennsylvania · US
Funding
Winship Cancer Institute Cancer Center Support GrantP30CA138292 · NCI · EMORY UNIVERSITY · PI Suresh S Ramalingam · 2009 to 2026
$47.5MTranslational Science Laboratory Shared ResourceP30CA138313 · NCI · MEDICAL UNIVERSITY OF SOUTH CAROLINA · PI RAYMOND N. DUBOIS · 2009 to 2026
$42.7MMechanisms of durable antitumor immunity via CD26hiCD4+ T cellsR01CA208514 · NCI · MEDICAL UNIVERSITY OF SOUTH CAROLINA · PI PAULOS, CHRYSTAL MARY · 2016 to 2020
$1.7MTargeting immune stroma interactions in pancreatic cancerR01CA228406 · NCI · EMORY UNIVERSITY · PI EL-RAYES, BASSEL, LESINSKI, GREGORY B. · 2019 to 2023
$1.7MCostimulatory mechanisms of antitumor Th17 cell immunityR01CA175061 · NCI · MEDICAL UNIVERSITY OF SOUTH CAROLINA · PI PAULOS, CHRYSTAL MARY · 2013 to 2017
$1.5MResearch Specialist Support of a Well-Established Cancer Immunotherapy Research Program Focused on Improving Adoptive T Cell Therapy (ACT)R50CA233168 · NCI · MEDICAL UNIVERSITY OF SOUTH CAROLINA · PI WYATT, MEGAN M · 2018 to 2022
$532kDefining the Role of CD26 in Checkpoint Blockaded Induced Tumor ImmunityR21DE029592 · NIDCR · MEDICAL UNIVERSITY OF SOUTH CAROLINA · PI PAULOS, CHRYSTAL MARY · 2020 to 2021
$411kModulation of the human pancreatic microenvironment by combined cytokine and immune checkpoint blockadeR21CA266088 · NCI · EMORY UNIVERSITY · PI EL-RAYES, BASSEL, LESINSKI, GREGORY B. · 2022 to 2023
$399kNCI NIH HHS P30 CA138292NCI NIH HHS P30 CA138313NCI NIH HHS R01 CA175061NCI NIH HHS R01 CA208514NCI NIH HHS R01 CA228406NCI NIH HHS R21 CA266088NCI NIH HHS R50 CA233168NIDCR NIH HHS R21 DE029592
Abstract
IL-17-producing antigen-specific human T cells elicit potent antitumor activity in mice. Yet, refinement of this approach is needed to position it for clinical use. While activation signal strength regulates IL-17 production by CD4
Indexed as
Inducible T-Cell Co-Stimulator ProteinInterleukin-17Receptors, Chimeric AntigenAnimalsCD28 AntigensHumansLymphocyte ActivationMicePhosphoenolpyruvateReceptors, Antigen, T-CellSignal TransductionTh17 CellsCD28 AntigensICOS protein, humanInducible T-Cell Co-Stimulator ProteinInterleukin-17PhosphoenolpyruvateReceptors, Antigen, T-CellReceptors, Chimeric AntigenCAR-Tcellular therapyICOSinducible costimulatorTCR signal strengthTh17
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.